Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM) -- Ignore unavailable to you. Want to Upgrade?

To: John Fairchild who wrote (75)	11/3/1998 9:02:00 PM
From: burner	Read Replies (1) \| Respond to of 134

Primate study nears completion Immune Network Research Ltd IMM Shares issued 19,970,452 Nov 3 close $0.20 Tue 3 Nov 98 News Release Mr. Victor Jones reports The blood plasma and tissue sampling has been completed on its phase II primate study of its proprietary monoclonal antibody 1F7. The study of the effects of mAb 1F7 on the immune system of macaques infected with a simian form of HIV follows on from an earlier study in macaques which showed beneficial effects of mAb 1F7. In that study mAb 1F7 appeared to increase the breadth and potency of the immune response, increase virus neutralizing antibodies and normalize the immune response against the SHIV viral infection. The macaque monkey is a preferred animal model for the study of HIV disease in humans. Arrangements have been made to analyze all of the plasma samples taken over the six month term of the macaque study using specialized equipment for low threshold detection of SHIV virus (viral load) and other measures of immune response to determine whether mAb 1F7 promotes restoration of an already impaired immune system. The study included a second series of injections of mAb 1F7 which may yield valuable data on repeated use of mAb 1F7 and characterization of mAb 1F7. A study of the effects of mAb 1F7 on the lymph nodes is also under way in collaboration with a university researcher. All animals survived the study and continue to be under close observation as part of related work by researchers at Harvard University. Certain animals may be used in further research in support of the application for the human clinical trial of mAb 1F7 under an investigational new drug protocol. The study is under direction of Dr. Sybille Muller of Immpheron, Inc., the company's partner on the mAb 1F7 project. Dr. Muller published results of the earlier study in the prestigious Proceedings of the National Academy of Science USA (PNAS Vol. 95 pp. 276-281, Jan. 6, 1998). Results of the just completed study are anticipated in the next few weeks and will similarly be prepared for publication. Planning for further research and the initial human clinical trial is under way.

To: John Fairchild who wrote (75)	2/3/1999 4:44:00 PM
From: Tom Hess	Read Replies (1) \| Respond to of 134

Looks like we are finally seeing some movement on result analysis. Immune Network progress on phase II study, private placement Immune Network Research Ltd IMM Shares issued 20,370,452 Feb 2 close $0.10 Wed 3 Feb 99 News Release VANCOUVER, B.C. - The Company is very pleased to announce that arrangements have been made to test the plasma samples from the Phase II macaque study of the Company's patented monoclonal antibody 1F7 (mAb 1F7). These tests of the biological efficacy of antiviral immunity induced or restored by mAb 1F7 will use a highly sensitive polymerase chain reaction-based assay to determine the viral load in plasma samples from SHIV-infected monkeys. Arrangements for these tests were made by Immpheron, Inc., the Company's research partner on the project, through a collaboration with researchers at Harvard University. This collaboration will enable the plasma tests to be performed at the United States National Cancer Institute laboratory, part of the National Institute of Health. The Phase II study involved nine macaques, which are a recognized model of HIV disease in humans, observed over a period of over six months and treated with two series of injections with mAb 1F7. Results of the tests are to form part of the Company's intended application to the FDA for a clinical trial of mAb 1F7 as an Investigational New Drug. In a related study, research has commenced on lymph node samples from selected macaques in collaboration with researchers at Duke University Medical Centre. This study will investigate B-cell response to mAb 1F7. In the Phase I macaque study mAb 1F7 appeared to strengthen the immune response and may play a role by inducing the immune system to produce antibodies of different specificity. Research is ongoing into the mechanism of the patented mAb 1F7 through an evaluation of the virus neutralizing antibody levels observed in the earlier Phase I macaque study. A manuscript by Dr. Sybille Muller, Vice President of Immpheron and Director of the Company's research program, has been submitted to a recognized journal in the field of immunology and AIDS. On corporate matters, the Company has received regulatory approval for the private placement of $54,000 and the issue of 360,000 shares together with one year warrants for the purchase of an additional 180,000 shares all at a price of $0.15 per share. The Company concluded its arrangement with an investor relations firm at the end of last year. Victor J.E. Jones President THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE. Immune Network Research Ltd. 900 - 475 Howe St, Vancouver, BC, Canada V6C 2B3 Tel. (604) 689-3923 * Fax. (604) 684-5854 www.immunenetwork.com (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com